Clinical Trials Logo

Myelomatosis clinical trials

View clinical trials related to Myelomatosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05153330 Recruiting - Cancer Clinical Trials

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

NCT ID: NCT04782687 Recruiting - Multiple Myeloma Clinical Trials

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Start date: September 10, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.